--- title: "Adjuvant Endometrial Cancer NRG GY032 | Sutter Health" description: "A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Endometrial Cancer NRG GY032 # Adjuvant Endometrial Cancer NRG GY032 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT05640999). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER) ![Christopher U Jones, M.D., FACR](https://dyn.mktgcdn.com/p/6fMCH4vO97TB6M5QvU1pl5Qui1fViPD5KLLubfev_dQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Christopher U Jones, M.D., FACR Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Endometrial%20Cancer%20NRG%20GY032%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Endometrial Cancer GCT1184-03](https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-gct1184-03-2064306931) A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy **Status:** Open to Enrollment - Clinical trial ### [Advanced or Recurrent Endometrial Cancer MK2870-033](https://www.sutterhealth.org/research/clinical-trials/advanced-or-recurrent-endometrial-cancer-mk2870-033-2099135881) A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29) **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Gynecological Cancers CORT125134-557 BELLA](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-gynecological-cancers-cort125134-557-bella-2072220354) An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA) **Status:** Open to Enrollment - Clinical trial ### [Advanced Solid Tumors RAINFOL-01](https://www.sutterhealth.org/research/clinical-trials/advanced-solid-tumors-rainfol-01-2023025237) Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Endometrial Cancer NRG GY032"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#medicalwebpage","name":"Adjuvant Endometrial Cancer NRG GY032","description":"A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#breadcrumblist"},"mentions":[{"@type":"Person","name":"Christopher U Jones, M.D., FACR","url":"https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897#medicaltrial","name":"Adjuvant Endometrial Cancer NRG GY032","alternateName":"A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-endometrial-cancer-nrg-gy032-2020963897","description":"A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)","identifier":"NCT05640999","code":{"@type":"MedicalCode","codeValue":"NCT05640999","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT05640999","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Endometrial Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```